Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism

Kazuhide Hayakawa, Kenichi Mishima, Masanori Nozako, Mai Hazekawa, Keiichi Irie, Masayuki Fujioka, Kensuke Orito, Koji Abe, Nobuyoshi Hasebe, Nobuaki Egashira, Katsunori Iwasaki, Michihiro Fujiwara

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

We examined the neuroprotective mechanism of cannabidiol, non-psychoactive component of marijuana, on the infarction in a 4 h mouse middle cerebral artery (MCA) occlusion model in comparison with Δ9- tetrahydrocannabinol (Δ9-THC). Release of glutamate in the cortex was measured at 2 h after MCA occlusion. Myeloperoxidase (MPO) and cerebral blood flow were measured at 1 h after reperfusion. In addition, infarct size and MPO were determined at 24 and 72 h after MCA occlusion. The neuroprotective effect of cannabidiol was not inhibited by either SR141716 or AM630. Both pre- and post-ischemic treatment with cannabidiol resulted in potent and long-lasting neuroprotection, whereas only pre-ischemic treatment with Δ9-THC reduced the infarction. Unlike Δ9-THC, cannabidiol did not affect the excess release of glutamate in the cortex after occlusion. Cannabidiol suppressed the decrease in cerebral blood flow by the failure of cerebral microcirculation after reperfusion and inhibited MPO activity in neutrophils. Furthermore, the number of MPO-immunopositive cells was reduced in the ipsilateral hemisphere in cannabidiol-treated group. Cannbidiol provides potent and long-lasting neuroprotection through an anti-inflammatory CB1 receptor-independent mechanism, suggesting that cannabidiol will have a palliative action and open new therapeutic possibilities for treating cerebrovascular disorders.

Original languageEnglish
Pages (from-to)1488-1496
Number of pages9
JournalJournal of Neurochemistry
Volume102
Issue number5
DOIs
Publication statusPublished - Sep 2007
Externally publishedYes

Fingerprint

Cannabidiol
Cannabinoid Receptors
Peroxidase
Dronabinol
Middle Cerebral Artery Infarction
Cerebrovascular Circulation
rimonabant
Infarction
Reperfusion
Glutamic Acid
Blood
Microcirculation
Cerebrovascular Disorders
Cannabinoid Receptor CB1
Neuroprotective Agents
Cannabis
Neutrophils
Anti-Inflammatory Agents

Keywords

  • Cannabidiol
  • Cannabinoid
  • Cerebral blood flow
  • Cerebral ischemia
  • Glutamate
  • Myeloperoxidase

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism. / Hayakawa, Kazuhide; Mishima, Kenichi; Nozako, Masanori; Hazekawa, Mai; Irie, Keiichi; Fujioka, Masayuki; Orito, Kensuke; Abe, Koji; Hasebe, Nobuyoshi; Egashira, Nobuaki; Iwasaki, Katsunori; Fujiwara, Michihiro.

In: Journal of Neurochemistry, Vol. 102, No. 5, 09.2007, p. 1488-1496.

Research output: Contribution to journalArticle

Hayakawa, K, Mishima, K, Nozako, M, Hazekawa, M, Irie, K, Fujioka, M, Orito, K, Abe, K, Hasebe, N, Egashira, N, Iwasaki, K & Fujiwara, M 2007, 'Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism', Journal of Neurochemistry, vol. 102, no. 5, pp. 1488-1496. https://doi.org/10.1111/j.1471-4159.2007.04565.x
Hayakawa, Kazuhide ; Mishima, Kenichi ; Nozako, Masanori ; Hazekawa, Mai ; Irie, Keiichi ; Fujioka, Masayuki ; Orito, Kensuke ; Abe, Koji ; Hasebe, Nobuyoshi ; Egashira, Nobuaki ; Iwasaki, Katsunori ; Fujiwara, Michihiro. / Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism. In: Journal of Neurochemistry. 2007 ; Vol. 102, No. 5. pp. 1488-1496.
@article{7629b644a75f4fdfbc22e6a4d2d3b583,
title = "Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism",
abstract = "We examined the neuroprotective mechanism of cannabidiol, non-psychoactive component of marijuana, on the infarction in a 4 h mouse middle cerebral artery (MCA) occlusion model in comparison with Δ9- tetrahydrocannabinol (Δ9-THC). Release of glutamate in the cortex was measured at 2 h after MCA occlusion. Myeloperoxidase (MPO) and cerebral blood flow were measured at 1 h after reperfusion. In addition, infarct size and MPO were determined at 24 and 72 h after MCA occlusion. The neuroprotective effect of cannabidiol was not inhibited by either SR141716 or AM630. Both pre- and post-ischemic treatment with cannabidiol resulted in potent and long-lasting neuroprotection, whereas only pre-ischemic treatment with Δ9-THC reduced the infarction. Unlike Δ9-THC, cannabidiol did not affect the excess release of glutamate in the cortex after occlusion. Cannabidiol suppressed the decrease in cerebral blood flow by the failure of cerebral microcirculation after reperfusion and inhibited MPO activity in neutrophils. Furthermore, the number of MPO-immunopositive cells was reduced in the ipsilateral hemisphere in cannabidiol-treated group. Cannbidiol provides potent and long-lasting neuroprotection through an anti-inflammatory CB1 receptor-independent mechanism, suggesting that cannabidiol will have a palliative action and open new therapeutic possibilities for treating cerebrovascular disorders.",
keywords = "Cannabidiol, Cannabinoid, Cerebral blood flow, Cerebral ischemia, Glutamate, Myeloperoxidase",
author = "Kazuhide Hayakawa and Kenichi Mishima and Masanori Nozako and Mai Hazekawa and Keiichi Irie and Masayuki Fujioka and Kensuke Orito and Koji Abe and Nobuyoshi Hasebe and Nobuaki Egashira and Katsunori Iwasaki and Michihiro Fujiwara",
year = "2007",
month = "9",
doi = "10.1111/j.1471-4159.2007.04565.x",
language = "English",
volume = "102",
pages = "1488--1496",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism

AU - Hayakawa, Kazuhide

AU - Mishima, Kenichi

AU - Nozako, Masanori

AU - Hazekawa, Mai

AU - Irie, Keiichi

AU - Fujioka, Masayuki

AU - Orito, Kensuke

AU - Abe, Koji

AU - Hasebe, Nobuyoshi

AU - Egashira, Nobuaki

AU - Iwasaki, Katsunori

AU - Fujiwara, Michihiro

PY - 2007/9

Y1 - 2007/9

N2 - We examined the neuroprotective mechanism of cannabidiol, non-psychoactive component of marijuana, on the infarction in a 4 h mouse middle cerebral artery (MCA) occlusion model in comparison with Δ9- tetrahydrocannabinol (Δ9-THC). Release of glutamate in the cortex was measured at 2 h after MCA occlusion. Myeloperoxidase (MPO) and cerebral blood flow were measured at 1 h after reperfusion. In addition, infarct size and MPO were determined at 24 and 72 h after MCA occlusion. The neuroprotective effect of cannabidiol was not inhibited by either SR141716 or AM630. Both pre- and post-ischemic treatment with cannabidiol resulted in potent and long-lasting neuroprotection, whereas only pre-ischemic treatment with Δ9-THC reduced the infarction. Unlike Δ9-THC, cannabidiol did not affect the excess release of glutamate in the cortex after occlusion. Cannabidiol suppressed the decrease in cerebral blood flow by the failure of cerebral microcirculation after reperfusion and inhibited MPO activity in neutrophils. Furthermore, the number of MPO-immunopositive cells was reduced in the ipsilateral hemisphere in cannabidiol-treated group. Cannbidiol provides potent and long-lasting neuroprotection through an anti-inflammatory CB1 receptor-independent mechanism, suggesting that cannabidiol will have a palliative action and open new therapeutic possibilities for treating cerebrovascular disorders.

AB - We examined the neuroprotective mechanism of cannabidiol, non-psychoactive component of marijuana, on the infarction in a 4 h mouse middle cerebral artery (MCA) occlusion model in comparison with Δ9- tetrahydrocannabinol (Δ9-THC). Release of glutamate in the cortex was measured at 2 h after MCA occlusion. Myeloperoxidase (MPO) and cerebral blood flow were measured at 1 h after reperfusion. In addition, infarct size and MPO were determined at 24 and 72 h after MCA occlusion. The neuroprotective effect of cannabidiol was not inhibited by either SR141716 or AM630. Both pre- and post-ischemic treatment with cannabidiol resulted in potent and long-lasting neuroprotection, whereas only pre-ischemic treatment with Δ9-THC reduced the infarction. Unlike Δ9-THC, cannabidiol did not affect the excess release of glutamate in the cortex after occlusion. Cannabidiol suppressed the decrease in cerebral blood flow by the failure of cerebral microcirculation after reperfusion and inhibited MPO activity in neutrophils. Furthermore, the number of MPO-immunopositive cells was reduced in the ipsilateral hemisphere in cannabidiol-treated group. Cannbidiol provides potent and long-lasting neuroprotection through an anti-inflammatory CB1 receptor-independent mechanism, suggesting that cannabidiol will have a palliative action and open new therapeutic possibilities for treating cerebrovascular disorders.

KW - Cannabidiol

KW - Cannabinoid

KW - Cerebral blood flow

KW - Cerebral ischemia

KW - Glutamate

KW - Myeloperoxidase

UR - http://www.scopus.com/inward/record.url?scp=34547870158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547870158&partnerID=8YFLogxK

U2 - 10.1111/j.1471-4159.2007.04565.x

DO - 10.1111/j.1471-4159.2007.04565.x

M3 - Article

C2 - 17437545

AN - SCOPUS:34547870158

VL - 102

SP - 1488

EP - 1496

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 5

ER -